跳到正文
European Pharmaceutical Review·· 20 天前AI 评分70

FDA发布细胞和基因治疗产品效价保证最终指南

​FDA finalises cell and gene therapy potency guidance

AI 导读

FDA发布《细胞和基因治疗产品效价保证》最终指南,替代2011年CGT产品效价检测指南。指南建议以基于科学和风险的全生命周期策略保证效价,涵盖原材料变异性控制、生产过程中检测和批次生物学活性实验室测定。文件还针对短货架期产品、病毒载体基因治疗和患者特异性治疗列出建议,并贯穿IND申报、BLA批准到上市后验证。

正文 · 原文

The FDA has issued final guidance outlining a science- and risk-based approach to potency assurance for cell and gene therapy (CGT) products, replacing its previous 2011 recommendations and setting out expectations across the product lifecycle.

AdobeStock_516172844

The US Food and Drug Administration (FDA) has issued final guidance to help manufacturers of cellular and gene therapies establish comprehensive strategies for ensuring product potency, from early development through commercialisation and post-market monitoring.

The guidance, Potency Assurance for Cellular and Gene Therapy Products, supersedes the FDA’s 2011 guidance on potency testing for CGT products. It provides recommendations for implementing a comprehensive, science- and risk-based strategy to ensure that products meet potency standards. 

The recommendations cover controls for raw material variability, testing during manufacturing and laboratory assays to confirm that each batch is biologically active in a way that matches its intended therapeutic effect. The guidance also addresses specific challenges associated with CGT manufacturing, including products with short shelf lives, viral vector-based gene therapies and patient-specific treatments.

The FDA recommends integrating potency considerations at every stage of product development and commercialisation, from early-phase investigational new drug (IND) submissions through biologics licence application (BLA) approval and post-market verification.

The guidance provides manufacturers with a clear, predictable roadmap for CGT development, supporting faster access to safe and effective therapies for patients, many of whom have limited treatment options. Karim Mikhail, Director of the FDA’s Center for Biologics Evaluation and Research, emphasised that patients “deserve the assurance that the product administered to them will perform as intended”, adding that innovation must be matched by the highest standards of product quality and patient safety.

来源:European Pharmaceutical Review · europeanpharmaceuticalreview.com

所属事件

查看事件全部
FDA发布CGT效力保证最终指南,替代2011年指南